Spirea develops the ELIVATE linker technology to enhance antibody-drug conjugates (ADCs) by significantly expanding the payload repertoire and improving drug pharmacokinetics. This technology addresses the limitations of current ADCs, enabling more effective targeted therapies for cancer and other diseases.
Funding
$5.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antibody-drug conjugates (ADCs) are limited by a restricted selection of payloads, suboptimal drug pharmacokinetics, and challenges in achieving precise drug delivery, which can compromise their therapeutic potential in treating cancer and other diseases. The limited payload repertoire constrains the ability to fully leverage diverse therapeutic modes of action.
Solution
Spirea is developing the ELIVATE linker technology to overcome these limitations and enhance the efficacy of ADCs. The ELIVATE linker is designed to significantly expand the accessible payload repertoire, enabling the incorporation of payloads with a broad variety of therapeutic modes-of-action. This multivalent linker technology allows for higher payload loading, optimizing the therapeutic potential of ADCs to better address multiple indications. ELIVATE-based ADCs also ensure excellent drug pharmacokinetics, achieving a long half-life and improved bioavailability, as well as precise drug delivery for targeted action at the cellular level.
Target Audience
Spirea's primary target audience includes ADC oncology companies, small molecule oncology companies, degrader/molecule glue oncology companies, antibody therapeutics companies, and inflammation/autoimmunity companies seeking to improve targeted delivery of therapeutics.
Features
- Multivalent ELIVATE linker technology engineered for precision ADC development
- Expanded payload repertoire, allowing access to a wider range of therapeutic modes of action
- Capability for higher payload loading to optimize therapeutic potential
- Enhanced drug pharmacokinetics, including a long half-life and improved bioavailability
- Precise drug delivery for targeted action at the cellular level
- Demonstrated in vivo efficacy with tumor regression and complete response in mouse xenograft models
- High monomeric purity and superior stability demonstrated ex-vivo
- Good rodent tolerability profiles at high doses